Current National Comprehensive Cancer Network guidelines recommend the use of a fluoropyrimidine, with or without bevacizumab, or for patients with RAS/BRAF wild-type tumours and left-sided disease, an anti-EGFR antibody [2]. Here, BRAF is linked to neoplasm.